Queen's University

Overview
Founded in 1841, Queen’s University in Kingston, Ontario is one of Canada’s leading research-intensive institutions, combining quality and intensity in research with excellence in undergraduate and graduate education.
Research is a core component of the mission of Queen’s University. A member of the U15, a group of Canada’s leading research-intensive universities, Queen’s ranks highly in terms of research funding and research intensity amongst universities nationally.
Their commitment to research excellence is evident in the many exceptional national and international accolades awarded to their researchers, most recently Queen’s Professor Emeritus Dr. Arthur B. McDonald was awarded the 2015 Nobel Prize in Physics – with co-recipient Takaaki Kajita of Japan – in Stockholm, Sweden.
This excellence, found across disciplines – from health care, the environment, materials, energy, law, economics, culture, and many others – attracts the best students, the best faculty, and the best collaborators from local and global communities, other institutions, government, and industry.
Through their diverse programs, Queen’s university promotes social innovation, fosters creative expression, and explores how societies work best. And it’s this culture of excellence that has made Queen’s one of Canada’s leading research universities.
Queen’s Partnerships and Innovation
The Queen’s Partnerships and Innovation (QPI) team supports the advancement of partnerships, research collaborations, and knowledge mobilization as well as innovation, entrepreneurship, and economic development. The QPI team develops and facilitates partnerships with industry, governments, not-for-profit organizations, and other academic institutions to advance the research enterprise at Queen’s and the commercialization of inventions, and to strengthen the regional innovation ecosystem in Kingston and Eastern Ontario. 
With support from external funding, the QPI team offers numerous services, resources and programs to support entrepreneurs, including those from Queen’s, and to accelerate the growth of startups and small to medium-sized enterprises (SMEs) within Kingston and Eastern Ontario. The team has transformed more than 1,000 invention disclosures into hundreds of technologies covered by at least one patent; additionally, the team has supported the founding and-or acceleration of hundreds of startups and SMEs in the Kingston region.

<h1 id="background">Background</h1>
Approximately 12.9% of US women will develop invasive breast cancer over the course of their lifetime. There are currently over 3.8 million breast cancer survivors in the United States, and the American Cancer Society estimates that over 280,000 new cases of invasive breast cancer will be diagnosed in 2021. While the death rates have decreased in recent years, breast cancer is still the second leading cause of cancer death in women.
Breast cancer is a heterogeneous disease, so determining an accurate and specific prognosis is essential to ensure that breast cancer patients receive the most effective course of treatment. A prognosis is usually based on a combination of clinical characteristics (eg: tumor size and grade, patient age) and histopathologic features.
The majority of breast cancers express the estrogen receptor (ER+) and are responsive to endocrine therapies which impair estrogen signaling. Tamoxifen, a selective estrogen receptor modulator (SERM), has been the standard of care for ER+ patients for more than 30 years. Tamoxifen has decreased recurrence rates by nearly half and has reduced mortality by about one-third1. However, approximately one quarter of women treated with tamoxifen relapse within 10 years of treatment1.
These data demonstrate that resistance to endocrine therapy continues to be an important clinical concern and that ER status is insufficient to predict treatment response. To date, several multigene expression profiling assays have been developed as prognostic tools for ER+ patients, including OncotypeDX, Prosigna and Mammaprint. While these tests stratify ER+ patients, their primary role is to identify individuals who do not need chemotherapy and they are not normally used to influence endocrine therapy decisions.
There is an urgent need for improved prognostic tests due to risk of recurrence and limitations of current tests. Such tests should have robust biomarkers capable of predicting patient response to endocrine therapy to enable improve treatment and maximize survival.
<ol>
<li>Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771-84.</li>
</ol>
<h1 id="technology-overview">Technology Overview</h1>
Recent studies have demonstrated that the expression and activation of the glucocorticoid receptor (GR) has a direct impact on the regulation of many ER target genes, due to the crosstalk between GR and ER as transcriptional activators. The coactivation of these receptors leads to the recruitment of GR to ER DNA binding sites, which can have either cooperative or antagonistic gene-specific outcomes1. In ER+ breast cancer cells which express GR, the activation of GR in addition to ER results in the increased expression of pro-differentiation genes, which is associated with improved relapse-free survival in ER+ breast cancer patients1. GR also impedes estrogen-stimulated cell growth by directly blocking the recruitment of transcriptional coactivators to ER-bound enhancers, repressing estrogen-activated gene transcription2.
Overall, it appears that GR promotes a more indolent phenotype in ER+ breast cancer via the modulation of ER-directed gene transcription. The loss of this modulation could result in increased cell survival and proliferation, even in response to ER-targeted therapies. For example, low GR expression has been associated with worse patient outcomes in ER+ breast cancers. It has been established that GR protein is frequently decreased in breast tumors and that lower GR expression is associated with higher tumor grade3. 
Researchers at Queen’s University have identified that methylation of the GR gene (NR3C1) promoter is a common event which results in the downregulation of GR in breast cancer4. While the GR promoter is not methylated in ordinary mammary tissue, it is methylated in approximately 15% of breast tumors, most of which are ER+4. A multiplexed bisulfite sequencing assay has been developed for detecting GR promoter methylation as a prognostic tool for use in ER+ breast cancer patients5. This next-generation sequencing (NGS) approach can detect GR promoter methylation with a limit of detection as low as 1% tumor cells5. By applying this assay to an established clinical trial cohort, Queen’s researchers discovered that the methylation of specific NR3C1 promoter regions can have positive or negative prognostic value in ER+ patients (Figure 1). This may be explained by region C methylation being inversely correlated with methylation in other regions, including region U5. These data support the idea that decreased methylation across the NR3C1 promoter is associated with better outcomes in ER+ patients.
<img src="https://s3-eu-west-1.amazonaws.com/assets.in-part.com/technologies/figures/9IkvLPbXSe6apbaDvnnX_GR-Figure-1.png" alt="Figure 1: Methylation of the GR bisulfite sequencing C and U regions and patient outcome." />
GR was also investigated as a marker in an independent cohort assembled by Kaplan‑Meier plotter5. ER+ patients with low GR‑expressing tumors exhibited an increased risk of breast cancer‑related death compared to those with high GR expression (Figure 2). Decreased GR expression was also found to be detrimental in ER+ patients treated with tamoxifen, as it was marginally associated with poor overall survival and significantly associated with increased relapse risk (Figure 2). Therefore, this multiplex bisulfite sequencing assay could be used to determine GR expression in ER+ tumors and predict treatment response. Additionally, this assay could also be used as a companion diagnostic for selective estrogen receptor degraders (SERDs) by identifying patients who are unlikely to respond to SERM treatment due to altered GR expression.
<img src="https://s3-eu-west-1.amazonaws.com/assets.in-part.com/technologies/figures/QfekCiZqTavYHH1HBoJM_GR-Figure-2.png" alt="Figure 2: Kaplan-Meier curves of survival in ER+ breast cancer patients." />
<ol>
<li>West DC, et al. GR and ER coactivation alters the expression of differentiation genes and associates with improved ER+ breast cancer outcome. Mol Cancer Res. 2016;14:707–19.</li>
<li>Yang F, et al. Glucocorticoid receptor: MegaTrans switching mediates the repression of an ERα-regulated transcriptional program. Mol Cell. 2017;66:321–31 e6.</li>
<li>Buxant F, et al. Estrogen receptor, progesterone receptor, and glucocorticoid receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer. Appl Immunohistochem Mol Morphol. 2010;18:254–7.</li>
<li>Nesset KA, et al. Frequent promoter hypermethylation and expression reduction of the glucocorticoid receptor gene in breast tumors. Epigenetics. 2014;9:851–9.</li>
<li>Snider H, et al. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer. Clinical Epigenetics. 2019;11:155.</li>
</ol>
<h1 id="benefits">Benefits</h1>
<ul>
<li>Novel prognostic tool for ER+ breast cancer patients</li>
<li>Ability to provide both positive and negative prognostic value based on methylation in specific promoter regions</li>
</ul>
<h1 id="applications">Applications</h1>
<ul>
<li>Companion diagnostic for SERD therapies</li>
<li>Prognostic tool for ER+ patients</li>
<li>Potential applications in other breast cancers, including TNBC</li>
</ul>
<h1 id="opportunity">Opportunity</h1>
 Seeking exclusive licensee, research collaborator or venture investment.